Vyjuvek wins conditional backing in Poland, tied to price cuts and an outcomes guarantee. https://www.mattheneus.com/editorial/aotmit-vyjuvek-conditional-reimbursement-price-outcomes-guarantee-gem3-2026-09-18 #HTA #Pharma #HealthEconomics

Poland’s AOTMiT backs Vyjuvek reimbursement, but only with price cuts and an outcomes guarantee. #HTA #Pharma #RegulatoryAffairs https://www.mattheneus.com/editorial/aotmit-vyjuvek-conditional-reimbursement-price-outcomes-guarantee-gem3-2026-09-18

Polish HTA agency backs Vyjuvek only with price cuts and an outcomes guarantee, showing how access can hinge on evidence-linked risk sharing. https://www.mattheneus.com/editorial/aotmit-vyjuvek-conditional-reimbursement-price-outcomes-guarantee-gem3-2026-09-18 #HTA #Pharma #RegulatoryAffairs

Poland backs Vyjuvek only with price cuts and an outcomes guarantee, showing how uncertainty is reshaping reimbursement. #HTA #Pharma #HealthEconomics https://www.mattheneus.com/editorial/aotmit-vyjuwek-conditional-reimbursement-price-outcomes-guarantee-gem3-2026-09-18

Cochrane finds no clear reduction in anastomotic leakage from transanal tubes after rectal cancer surgery. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/cochrane-transanal-tube-rectal-cancer-leakage-stoma-subgroup-2026-09-22

Modern radiotherapy evaluations need three separate lenses: reporting, bias and uncertainty. https://www.mattheneus.com/editorial/modern-radiotherapy-economic-evaluation-three-dimension-review-2026-09-22 #HTA #HealthEconomics #EvidenceSynthesis

Australia backed odevixibat after a price and risk-sharing reset reshaped the reimbursement case. https://www.mattheneus.com/editorial/pbac-odevixibat-bylvay-alagille-early-resubmission-recommendation-2026-08-21 #HTA #RegulatoryAffairs #Pharma

A 4,003-patient network meta-analysis links intravascular imaging to fewer coronary events in calcified lesions. https://www.mattheneus.com/editorial/pubmed-intravascular-imaging-calcified-coronary-lesions-network-meta-analysis-2026-09-17 #HTA #NMA #EvidenceSynthesis #Pharma

Before a tissue-engineered dialysis graft reaches market, price the interventions it must prevent. https://www.mattheneus.com/editorial/tissue-engineered-dialysis-graft-intervention-threshold-early-economic-evaluation-2026-09-21 #HTA #HealthEconomics #EvidenceSynthesis

France traced end-of-life safety failures across 385 care incidents. See the patterns regulators and evidence teams should notice. https://www.mattheneus.com/editorial/has-end-of-life-serious-care-incidents-descriptive-safety-analysis-2026-09-16 #HTA #RWE #RegulatoryAffairs

Clinical-trial software providers face a dedicated UK inspection dossier. See what the new MHRA expectations mean. https://www.mattheneus.com/editorial/mhra-computerised-clinical-trial-systems-inspection-dossier-2026-09-22 #HTA #RegulatoryAffairs #Pharma

An ICU cost review arrived already outdated. See why evidence cutoffs matter for remifentanil versus fentanyl decisions. https://www.mattheneus.com/editorial/remifentanil-fentanyl-icu-economic-evidence-update-search-cutoff-2026-09-22 #HTA #HealthEconomics #EvidenceSynthesis

#USUKTradeAgreement #NICE #NHS #HEOR #HealthandSocialCareCommittee #ImpactAssessment #brandedmedicines #NuffieldTrust #tariffs #medicines #newmedicines #commissioningframework #HTA #NICEcosteffectivenessthreshold #NHSbudgets #ScienceInnovationandTechnologyCommittee #NHSefficiency
zurl.co/V9PQM

🌍⚖️ Join the EIEE SIG webinar on Health Inequality Aversion in Asia — exploring early findings, methodological challenges, and future directions for equity-informed HTA.

📅 Sept 23 | ⏰ 11 AM–12 PM UTC
💻 us02web.zoom.us/j/8452086562...

#HealthEconomics #HTA #GlobalHealth #UHC #Equity

⚠️🎣 Invoice phishing abuses mshta.exe

Spanish lures launch hidden #HTA files for reconnaissance, HTML smuggling and credential-stealing payloads.

🔗 read more: gbhackers.com/new-ph...

#ransomNews #cyberthreats #Phishing

How widely are private sector-led submissions (PLS) used to support HTA?

👉 Our latest GEAR blog explores the global landscape of HTA and PLS, with an online dashboard to explore country- and jurisdiction-level classifications: www.gear4health.com/blog/detail/45

#HTA #HealthPolicy #GEAR

As reimbursement criteria tighten and payer landscapes evolve, #HTA has become one of the deciding factors for market access in pharma MedTech.

Learn more: iebrain.com/service/cons...

#MarketAccess #HTA

Final reminder — PMI’s Market Access Workshop takes place this Thursday, 17 September.

Supported by Salutem Insights, with Dr Claire Barry speaking alongside voices from NCPE, industry and patient advocacy.

Limited spaces remaining.

Book via PMI: lnkd.in/dTu_Jr4C

#MarketAccess #HTA #CPD

What will AI mean for the future of HTA?

At HITAP’s latest Open Talk, Prof. Alec Morton explored how AI could reshape health economic modelling, policymaking and the role of HTA researchers.

📺 Watch the full talk: youtu.be/55moB5PkiTQ

#HTA #AI #HealthEconomics

🧬 Join the IHEA webinar with Dr. Scott Grosse on evaluating the cost-effectiveness of adult population genomic screening.

📅 Sept 10, 2026 | ⏰ 4–5 PM UTC

🎥 www.healtheconomics.org/event/eviden...

#HealthEconomics #Genomics #HTA #IHEA